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Abstract
Purpose Access to trastuzumab, a valuable anti-cancer treatment, can be limited by cost. The primary aim of this study 
was to evaluate and compare the PK profiles of CT-P6, a biosimilar of trastuzumab, and US-licensed reference trastuzumab 
 (Herceptin®) in healthy subjects. Secondary study aims included comparison of the safety and immunogenicity of CT-P6 
and reference trastuzumab in these subjects.
Methods We performed a single-dose, randomised, double-blind, parallel group study (NCT02665637) comparing CT-P6 
with reference trastuzumab (6 mg/kg, 90 min intravenous infusion) in 70 healthy adult males. Pharmacokinetics, safety and 
immunogenicity were evaluated up to 10 weeks post-dose. Primary endpoints were area under the serum concentration–time 
curve (AUC) from time 0 to infinity (AUC inf); AUC from time 0 to last quantifiable concentration (AUC last); and observed 
maximum serum concentration (Cmax). The pre-determined equivalence criterion was a 90% confidence interval of 80–125% 
for ratios of geometric least squares (LS) means.
Results Equivalence of CT-P6 and reference trastuzumab was demonstrated. Ratios (CT-P6/reference trastuzumab) of geo-
metric LS means (90% confidence interval) were: AUC inf 99.05 (93.00, 105.51); AUC last 99.30 (92.85, 106.20); Cmax 96.58 
(90.93, 102.59). Safety profiles were similar; treatment-emergent adverse events occurred in ten subjects (28.6%) in the 
CT-P6 group and 11 (31.4%) in the reference trastuzumab group. No serious adverse events or deaths occurred. No subjects 
tested positive for anti-drug antibodies.
Conclusions These data add to the totality of evidence required to demonstrate biosimilarity. A phase III study of CT-P6—in 
which equivalent neoadjuvant efficacy to reference trastuzumab has been demonstrated—is ongoing.
Keywords Biosimilar · CT-P6 · Equivalence · Pharmacokinetics · Safety · Trastuzumab
Introduction
Trastuzumab, a recombinant humanised monoclonal anti-
body (mAb), targets the human epidermal growth factor 
receptor 2 (HER2), a receptor tyrosine kinase [1]. Although 
HER2 has no known ligand it is able to dimerise, a process 
that can be induced by HER2 over-expression [2]. Dimerisa-
tion and subsequent HER2-mediated signalling increase cell 
proliferation and inhibit apoptosis [2]. HER2 over-expres-
sion occurs in up to 30% of all breast cancers [3] and at a 
similar rate in gastric cancers [4]. Over-expression is associ-
ated with decreased time to recurrence and poorer prognosis 
in breast cancer [3, 5], and may be linked to worse prognosis 
and increased recurrence in gastric cancer [4, 6].
Trastuzumab binding to HER2 leads to antibody-depend-
ent cell-mediated cytotoxicity (ADCC) and inhibition of 
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cell proliferation [1]. Originator or ‘reference’ trastuzumab 
 (Herceptin®) is approved for the adjuvant treatment of 
HER2-positive (HER2 +) breast cancer, the treatment of 
HER2 + metastatic breast cancer (MBC) and HER2 + meta-
static gastric or gastroesophageal junction adenocarcinoma 
in the USA [7], and of HER2 + MBC, HER2 + early breast 
cancer (EBC) and HER2 + metastatic gastric or gastroe-
sophageal junction adenocarcinoma in Europe [8]. The 
combination of reference trastuzumab with chemotherapy in 
HER2 + breast cancer has been shown to improve response 
rates, reduce recurrence risk and increase survival, com-
pared with chemotherapy alone [9–13], findings that support 
the inclusion of this approach in European [9, 14] and USA 
[15–17] treatment guidelines. Such combination therapy also 
increases survival, compared with chemotherapy alone, in 
advanced HER2 + gastric or gastroesophageal junction can-
cers [18], as reflected in clinical guidelines [19–21].
The use of biological therapies has advanced cancer treat-
ment but also significantly increased treatment costs, with, 
for example, one course of reference trastuzumab costing 
approximately US $70,000 [22]. When considered along-
side increasing cancer prevalence, particularly in develop-
ing nations, and a growing and ageing global population, 
this financial burden to healthcare systems may soon reach 
unsustainable levels [23, 24]. As reference product patents 
expire, biosimilar products can be developed and introduced, 
providing a potential means to reduce this financial burden 
[25] and enhance patient access to treatment [26]. A biosimi-
lar is a biological medicinal product similar to one already 
authorised (the ‘reference product’) and expected to have 
similar clinical efficacy and safety profiles, as determined 
by comprehensive comparability assessments [27]. CT-P6 
(CELLTRION, Incheon, Republic of Korea) is a biosimilar 
of reference trastuzumab, already approved in South Korea 
for the same indications as the reference product [28]. CT-P6 
has been found to be similar to reference trastuzumab in 
in vitro studies, including with respect to HER2 binding 
affinity, ADCC and anti-proliferation activity. CT-P6 also 
exhibited a similar profile to reference trastuzumab in in vivo 
toxicology studies [CELLTRION Inc., data on file].
Due to the complexity of manufacturing biological prod-
ucts, it is impossible to create a biosimilar that is identical 
to a reference product, just as no two batches of reference 
product can be identical. It is, therefore, necessary to demon-
strate that no clinically meaningful differences are expected 
between the two, before a biosimilar can be approved by 
regulatory authorities [27, 29, 30]. This includes demonstra-
tion of analytical and non-clinical similarity as well as com-
parable clinical pharmacokinetics (PK), efficacy, safety and 
immunogenicity [27, 30]. The US Food and Drug Admin-
istration (FDA) requires that at least one clinical PK study 
demonstrating similarity to an FDA-licensed product is con-
ducted [29], while the European Medicines Agency (EMA) 
also considers a comparative clinical PK study to be essen-
tial [27]. The primary aim of the current study was to evalu-
ate and compare the PK profiles of CT-P6 and US-licensed 
reference trastuzumab in healthy subjects. Secondary study 
aims were to assess additional PK parameters and the safety 
and immunogenicity of CT-P6 and reference trastuzumab 
in these subjects.
Materials and methods
Study design and ethics
This phase I single-dose study was approved by an inves-
tigational review board (IntegReview IRB; Austin, TX, 
USA) and performed in accordance with the ethical stand-
ards as laid down in the 1964 Declaration of Helsinki and 
its later amendments or comparable ethical standards, and 
International Conference on Harmonization Good Clinical 
Practice guidelines. Informed consent was obtained from 
all individual participants included in the study. The study 
was a 10-week, double-blind, two-arm, parallel-group trial 
comparing CT-P6 with reference trastuzumab (Fig. 1). The 
study was conducted at two centres in the USA (PPD Phase 
I Clinic, Austin, TX and Anaheim Clinical Trials, Anaheim, 
CA). The trial was registered with ClinicalTrials.gov (Study 
Number NCT02665637).
Subject eligibility criteria
Eligible subjects were healthy males aged between 18 and 
55 years inclusive, with a body mass index of 18.0–29.9 kg/
m2 and a body weight of 55.0–99.9 kg. The trial included a 
sub-population of subjects of Japanese ethnicity within each 
treatment arm, in line with Japanese Pharmaceuticals and 
Medical Devices Agency requirements. Exclusion criteria 
encompassed a number of medical conditions, including a 
history or presence of hypersensitivity; allergy; clinically 
significant atopic allergy; infection requiring systemic anti-
infective treatment within 14 days of study randomisation; 
a history of congestive heart failure; and an abnormal left 
ventricular ejection fraction (LVEF) within 3 weeks of study 
randomisation. Subjects were excluded from the study if they 
had any previous exposure to mAbs or current use of biolog-
ics. Subjects were also excluded if they had used prescrip-
tion or non-prescription medications or dietary supplements 
within 7 days or five half-lives prior to dosing (any herbal 
supplements were discontinued 28 days before dosing), or 
treatment with an investigational drug or participation in a 
clinical trial within 30 days or five half-lives prior to dos-
ing. Moderate or heavy tobacco smokers were not eligible 
for the study, nor were subjects exhibiting evidence of drug 
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or alcohol abuse. (For a full list of inclusion and exclusion 
criteria see Online Resource Tables A1 and A2).
Sample size, randomisation and blinding
The study was powered to demonstrate PK equivalence 
of CT-P6 and reference trastuzumab in primary PK end-
points [area under the serum concentration–time curve 
from time 0 to infinity (AUC inf), area under the serum con-
centration–time curve from time 0 to the last quantifiable 
concentration (AUC last), and the observed maximum serum 
concentration (Cmax)]. Thirty-one subjects were required in 
each treatment arm to provide at least 80% power for a 90% 
confidence interval (CI) for the ratio of AUC inf, AUC last, and 
Cmax within the equivalence margin of 80–125% [assuming 
a coefficient of variation of 30% and a ratio of geometric 
least squares (LS) means of 1]. Assuming a 10% dropout 
rate, a sample size of approximately 70 subjects (n = 35 per 
treatment arm) was required.
After an initial screening visit (conducted between day 
−21 and day −2), subjects were admitted to the study cen-
tre to undergo baseline assessments and confirm eligibility 
(day −1). Eligible subjects were then randomised (day 1) in 
a 1:1 ratio to receive either CT-P6 or reference trastuzumab 
(Fig. 1). Randomisation codes were provided by PPD before 
the study began and were created using the PROC PLAN 
procedure in  SAS® version 9.2 (SAS Institute Inc., Cary, 
NC, USA). Two sets of sealed code-break envelopes were 
supplied: one was retained at the study centre and one at 
the PPD Pharmacovigilance Reporting Department. The 
randomisation code was only broken after all final clini-
cal data were recorded and all subjects were assigned to 
analysis sets. This randomisation included stratification by 
race (Japanese and non-Japanese). Dosing was conducted 
in a double-blinded fashion. All dosing solutions were pre-
pared in identical infusion bags by a separate, designated, 
unblinded pharmacist and supplied to the treating clinician 
in a blinded manner.
Experimental procedures
Subjects received a single dose of either CT-P6 (6 mg/
kg, Lot Number 13A3C003; CELLTRION Inc., Incheon, 
Republic of Korea) or US-licensed reference trastuzumab 
 (Herceptin®; 6 mg/kg, Lot Number 3014296; Genentech 
Inc., South San Francisco, CA, USA), by intravenous 
infusion for 90 min (± 5 min) on day 1. Oral paracetamol 
(650 mg) was administered 30–60 min prior to infusion to 
reduce the risk of infusion-related reactions (IRRs). Subjects 
remained in the study centre until 96 h post-infusion. Further 
assessments of PK, safety and immunogenicity parameters 
were conducted up to 10 weeks post-dose, on an outpatient 
basis, with a final visit for end-of-study assessments on day 
71 (Fig. 1).
Study endpoints
Primary endpoints
Blood samples for PK analysis were taken on days 1 (pre-
dose then 1.5, 3, 6 and 12 h after infusion start), 2 (24 h 
after infusion start), 3, 5, 8, 15, 22, 29, 50 and 71. Non-
compartmental trastuzumab serum PK parameters were 
Screening visit: eligibility assessment (days -21 to -2)
Enrolment and admission of eligible subjects (day -1)
n = 70
Randomisation (day 1)
CT-P6 (n = 35), reference trastuzumab (n = 35)
In-house dosing and assessmentsa (days 1–5)
CT-P6 (n = 35), reference trastuzumab (n = 35)
Safety populationb
CT-P6 (n = 35), reference trastuzumab (n = 35)
PK populationc
CT-P6 (n = 35), reference trastuzumab (n = 35)
Study completion/end of
study assessmentsa (day 71)
CT-P6 (n = 35), reference
trastuzumab (n = 34)
Discontinued study
CT-P6 (n = 0), reference 
trastuzumab (n = 1; 
discontinued on day 41 
due to personal reasons)
Outpatient assessmentsa (days 8, 15, 22, 29, 50)
Fig. 1  Study design and subject flow. aAssessments included blood 
samples for PK analysis [days 1 (pre-dose then 1.5, 3, 6, 12 h after 
infusion start), 2 (24 h after infusion start), 3, 5, 8, 15, 22, 29, 50 and 
71]; physical examination (days 3 and 71); clinical laboratory tests 
(days 2, 3, 5, 8, 15, 22, 29, 50 and 71); measurement of vital signs 
(days 1, 2, 3, 5, 8, 15, 22, 29, 50 and 71); electrocardiogram (days 
1, 3, 5, 15, 29 and 71); cardiac function (day 71); and levels of anti-
drug antibody and neutralising antibody [days 1 (pre-dose), 50 and 
71]. Adverse event monitoring was conducted for the duration of 
the study. bSafety population: all randomised subjects who received 
a complete or partial dose of either CT-P6 or reference trastuzumab. 
cPK population: all subjects who received a complete dose of either 
CT-P6 or reference trastuzumab and from whom at least one post-
treatment PK sample with a concentration above the lower limit of 
quantification for trastuzumab was collected. PK pharmacokinetic
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obtained for each treatment group. Primary PK endpoints 
were AUC inf, AUC last, and Cmax. The pre-determined cri-
terion used to establish PK equivalence of CT-P6 and ref-
erence trastuzumab (with respect to AUC inf, AUC last and 
Cmax) was a 90% CI for the ratio of geometric LS means 
of between 80 and 125%.
Secondary PK endpoints
Secondary PK endpoints included the percentage of the 
area extrapolated for calculation of AUC inf (%AUC ext), 
time to Cmax (Tmax), volume of distribution during the ter-
minal phase (Vz), terminal elimination rate constant (λz), 
terminal elimination half-life (t½), and total body clear-
ance (CL).
Additional secondary endpoints: safety 
and immunogenicity
Safety endpoints included assessment of adverse events 
(AEs), IRRs, clinical laboratory test results, vital signs, elec-
trocardiogram (ECG), New York Heart Association clas-
sification, LVEF and physical examination. Immunogenic-
ity was evaluated via measurement of anti-drug antibody 
(ADA) and neutralising antibody (NAb) levels (Fig. 1).
Data analysis
Statistical analyses were conducted using  SAS® version 
9.2. PK data were analysed using  Phoenix®  WinNonlin® 
Version 6.2.1 (Pharsight Corporation, St Louis, MO, USA). 
During analysis, PK samples taken before administration 
of CT-P6 or reference trastuzumab in which serum trastu-
zumab concentrations were below the lower limit of quan-
tification (LLOQ) were listed as zero. For those taken after 
administration of CT-P6 or reference trastuzumab, the first 
value below the LLOQ was listed as LLOQ. Any subse-
quent serum concentration values below the LLOQ were 
listed as ‘missing’. Log-transformed primary PK endpoints 
(AUC inf, AUC last, and Cmax) were analysed using an analysis 
of covariance (ANCOVA) model, with treatment as a fixed 
effect and race (Japanese and non-Japanese) as a covariate. 
The difference in geometric LS means between treatment 
groups and the associated 90% CIs was determined. These 
values were then back-transformed to calculate the ratio of 
geometric LS means and associated 90% CIs.
AEs were coded using the Medical Dictionary for Regu-
latory Activities, version 18.1 and intensity gradings were 
recorded based on Common Terminology Criteria for 
Adverse Events, (CTCAE, version 4.03).
Analysis populations
All subjects who received a complete dose of either CT-P6 
or reference trastuzumab, and from whom at least one 
post-treatment PK sample with a concentration above the 
LLOQ for trastuzumab was collected, were included in the 
PK analysis population. The safety population comprised 
all randomised subjects who received a complete or partial 
dose of either CT-P6 or reference trastuzumab.
Results
Subjects
Seventy healthy male subjects (24 of Japanese ethnicity) 
were recruited into the study, which was conducted between 
22 December 2015 and 29 April 2016. Each treatment arm 
consisted of 12 Japanese subjects and 23 non-Japanese sub-
jects (Table 1). Sixty-nine of the 70 enrolled subjects com-
pleted the study; one subject in the reference trastuzumab 
group was discontinued (due to personal reasons). All 70 
subjects met the criteria for inclusion in both the PK and 
safety populations (Fig. 1).
PK
Equivalence of CT-P6 and reference trastuzumab in healthy 
male subjects was demonstrated, with 90% CIs for the geo-
metric LS mean ratios of AUC inf, AUC last, and Cmax within 
the predefined range of 80–125% (Table 2). Similar results 
were obtained in the Japanese sub-population (Online 
Resource Table A3). The overall PK profile of trastuzumab 
was similar in both the CT-P6 and reference trastuzumab 
groups (Fig. 2) and secondary PK endpoints (%AUC ext, 
Tmax, t½, λz, Vz, and CL) were comparable between treat-
ment groups (Table 3).
Safety
Overall safety profiles were similar for both CT-P6 and ref-
erence trastuzumab, and both agents were well tolerated. In 
total, 37 treatment-emergent adverse events (TEAEs) were 
reported: ten subjects (28.6%) reported TEAEs in the CT-P6 
group, compared with 11 subjects (31.4%) in the reference 
trastuzumab group. Headache was the most common TEAE, 
reported by two subjects (5.7%) in the CT-P6 group and 
three subjects (8.6%) in the reference trastuzumab group. A 
total of ten subjects (14.3%) reported a TEAE considered 
related to study drug (five subjects in each treatment group) 
(Table 4).
With the exception of one subject in the reference 
trastuzumab group who experienced Grade 2 nausea and 
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vomiting, all TEAEs were Grade 1 in severity. All TEAEs 
resolved by the end of the study, with the exception of one 
instance in a subject in the reference trastuzumab group 
(Gilbert’s syndrome). No deaths, serious AEs, TEAEs of 
Grade 3 or higher, TEAEs due to cardiotoxicity, or TEAEs 
leading to study discontinuation occurred. Seven TEAEs 
relating to IRRs, hypersensitivity or anaphylactic reactions 
were reported (nausea, vomiting, chills, feeling of body 
temperature change, myalgia, dizziness, and headache). 
These seven TEAEs occurred in three subjects (4.3%), one 
in the CT-P6 group and two in the reference trastuzumab 
group. No treatment-related effects on clinical laboratory 
results, vital sign measurements, ECG results, or physical 
examination findings occurred in any subject. No nota-
ble changes in LVEF were observed on day 71 in either 
group. Finally, no signs or symptoms of cardiac dysfunc-
tion occurred in any subject at the time points assessed.
Immunogenicity
None of the subjects had a positive ADA test result; there-
fore, the NAb analysis was not applicable.
Table 1  Subject demographics 
(safety population)
SD standard deviation
Characteristic Overall (n = 70) CT-P6 group (n = 35) Reference tras-
tuzumab group 
(n = 35)
Age (years)
 Median 34.5 37.0 32.0
 Range 18–55 20–55 18–54
Sex, n (%)
 Male 70 (100.0) 35 (100.0) 35 (100.0)
Height (cm)
 Mean (SD) 175.2 (7.8) 175.7 (8.2) 174.8 (7.4)
 Range 159.6–192.6 159.6–192.6 160.3–191.8
Weight (kg)
 Mean (SD) 77.3 (9.9) 77.8 (8.6) 76.8 (11.2)
 Range 59.2–101.8 62.8–95.2 59.2–101.8
Body mass index (kg/m2)
 Mean (SD) 25.2 (2.8) 25.3 (2.7) 25.1 (3.0)
 Range 19.4–29.8 19.8–29.7 19.4–29.8
Ethnicity, n (%)
 Japanese 24 (34.3) 12 (34.3) 12 (34.3)
 White 34 (48.6) 19 (54.3) 15 (42.9)
 Black or African 
American
12 (17.1) 4 (11.4) 8 (22.9)
Table 2  Primary PK data (PK 
population)
An analysis of covariance was performed with the natural log-transformed PK data as the dependent vari-
able, treatment as a fixed effect, and race as a covariate
AUC inf area under the serum concentration–time curve from time 0 to infinity, AUC last area under the serum 
concentration–time curve from time 0 to the last quantifiable concentration, CI confidence interval, Cmax 
observed maximum measured serum concentration, LS least squares, PK pharmacokinetic
a The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of 
the ratio of adjusted geometric LS means (CT-P6/reference trastuzumab) and corresponding 90% CI values
PK parameter (unit) Geometric LS  meansa %  Ratioa (CT-P6/refer-
ence trastuzumab)
90%  CIa
CT-P6 (n = 35) Reference trastu-
zumab (n = 35)
AUC inf (h μg ml−1) 19523.05 19709.36 99.05 93.00, 105.51
AUC last (h μg ml−1) 18183.73 18312.53 99.30 92.85, 106.20
Cmax (μg ml−1) 127.95 132.48 96.58 90.93, 102.59
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Discussion
These data demonstrate that CT-P6 and reference trastu-
zumab were equivalent in healthy subjects, as measured 
by the primary PK endpoints AUC inf, AUC last, and Cmax. 
Similar results were seen in the Japanese sub-population. 
Secondary PK endpoints (%AUC ext, Tmax, t½, λz, Vz, and 
CL) were also comparable for CT-P6 and reference tras-
tuzumab. Both agents were well tolerated, with the safety 
profile of CT-P6 comparable to that of reference trastu-
zumab. Immunogenicity did not differ between treatment 
groups (none of the trial subjects exhibited a positive ADA 
test result).
The FDA and EMA require that biosimilarity is demon-
strated via a ‘stepwise approach’ that includes analytical, 
non-clinical and clinical data, with clinical evidence encom-
passing PK, efficacy, safety and immunogenicity. The impor-
tance of conducting a direct, comparative PK study between 
a biosimilar and the relevant reference product is highlighted 
by both regulatory agencies [27, 29]. Thus, these data repre-
sent an important component of the regulatory information 
required for approval of CT-P6 in Europe and the USA. In 
common with most PK studies, this trial was conducted in 
healthy, male volunteers. Healthy subjects were used in this 
study to avoid the potentially high variability of trastuzumab 
exposure that may occur in patients with breast or gastric 
cancer. Male subjects were recruited for ethical reasons; as 
most patients who receive trastuzumab are female, females 
should be preferentially protected from the possibility of 
developing antibodies to trastuzumab, which may preclude 
or reduce the effectiveness of future trastuzumab therapy.
Trastuzumab is an established treatment option for 
patients with HER2 + breast cancer [9, 14, 15, 17] and 
HER2 + gastric and gastroesophageal junction cancer 
[19–21]. In clinical trials, trastuzumab is associated with 
increased pathological complete response rates and event-
free survival rates when used as part of a neoadjuvant 
treatment regimen in early HER2 + breast cancer [31–33], 
and increased rates of disease-free and overall survival 
rates when used as a component of adjuvant treatment 
[10, 34, 35]. Addition of trastuzumab to chemotherapy in 
HER2 + MBC improves survival rates as well as increas-
ing time to disease progression, time to treatment failure 
and duration of response [36–38]. Efficacy in HER2 + MBC 
is also seen when trastuzumab is used as a monotherapy 
[39]. Despite these clinical findings, oncologists report that 
patient access to trastuzumab is sometimes restricted due 
to cost [26]. Assuming equivalent efficacy, biosimilars are 
more cost-effective than the corresponding reference prod-
uct, and their availability may, therefore, improve the finan-
cial sustainability of cancer treatment [23, 25] and improve 
patient access [26]. A recent study in Europe found that, 
on average, biosimilars were 15% less expensive than their 
corresponding reference product [40]. A Croatian budget 
impact analysis (BIA) that modelled the impact of the intro-
duction of biosimilar trastuzumab predicted savings of up 
to €0.69 million in the initial year of introduction into that 
country (assuming a 35% price discount), with up to 47 
extra patients able to access trastuzumab [41]. Data from 
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Fig. 2  Mean trastuzumab serum concentration-versus-time profiles 
a from 0 to 1200  h (50  days); b detailed view of 0–70  h. Data are 
means ± standard deviation. Data beyond day 50 (1200  h) are not 
shown, as these were below the lower limit of quantification for tras-
tuzumab
Table 3  Secondary PK data (PK population)
All data are means (standard deviation) unless otherwise specified
λz terminal elimination rate constant, AUC ext area extrapolated for cal-
culation of area under the serum concentration–time curve from time 
0 to infinity, CL total body clearance, PK pharmacokinetic, t½ termi-
nal elimination half-life, Tmax time to observed maximum measured 
serum concentration, Vz volume of distribution during the terminal 
phase
PK parameter (unit) CT-P6 (n = 35) Reference 
trastuzumab 
(n = 35)
AUC ext (%) 6.81 (1.17) 7.00 (2.52)
t½ (h) 189.31 (36.03) 183.68 (37.53)
Tmax, median (h) 1.55 1.52
λz (1 h−1) 0.0038 (0.0007) 0.0039 (0.0007)
Vz (l) 6.38 (1.42) 6.09 (1.71)
CL (l h−1) 0.0236 (0.0043) 0.0230 (0.0048)
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first-generation biosimilars prescribed in supportive cancer 
care [e.g. biosimilars of erythropoietins, erythropoiesis-
stimulating agent (ESA), or granulocyte-colony-stimulating 
factor (G-CSF) reference products] also demonstrate poten-
tial cost savings. For example, a BIA model of biosimilar 
ESA usage in Germany, France, Italy, Spain and the UK 
calculated a saving of up to €146 million, if all patients con-
verted to biosimilar ESA, potentially freeing up budget for 
reallocation to anti-cancer treatments [42]. Another analysis 
conducted in the same countries assessing the use of bio-
similar filgrastim estimated savings of €32.70 (1-day regi-
men) to €457.84 (14-day regimen), per treatment [43]. Use 
of erythropoietins and G-CSF increased following the intro-
duction of biosimilar versions, in particular in countries in 
which access to biological products is restricted. In the UK, 
patient access to filgrastim increased substantially due to the 
introduction of a biosimilar version, the cost-effectiveness of 
which led to changes in clinical guidelines [44].
A number of trastuzumab biosimilars are currently at 
various stages of development. However, the types and 
amounts of non-clinical and clinical data available for each 
agent vary considerably [28]. Several are currently in, or 
about to enter, late-stage clinical trials, including FTMB/
ABP 980, PF-05280014 and HD201 [28]. SB3 has recently 
been approved by the EMA [45] and MYL-1401O has been 
approved for use by the US FDA [46]. Others have not been 
developed or evaluated according to the stringent guide-
lines defined by regulatory authorities in the US, Europe 
and some other countries [27, 29] and, thus, may be more 
correctly termed ‘biomimics’ or ‘biocopies’ rather than bio-
similars [47].
A Phase III trial of CT-P6 is ongoing, in which the 
efficacy and safety of CT-P6 for neoadjuvant and adju-
vant treatment are being compared with those of reference 
trastuzumab in HER2 + EBC (NCT02162667). Results 
from the neoadjuvant period show that the efficacy of 
CT-P6 was equivalent to that of reference trastuzumab, 
and safety profiles were also similar [48]. The results of 
the present study, therefore, add to the totality of evidence 
regarding CT-P6 required by US and European regula-
tory authorities, in addition to addressing the specific 
US requirement of similarity to an FDA-licensed product 
with respect to clinical PK [29] and the EMA requirement 
for a comparative clinical PK study [27].
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Table 4  TEAEs (safety 
population)
Data presented are n (%)
TEAE treatment-emergent adverse event
a TEAEs reported in more than one subject overall
CT-P6 (n = 35) Reference 
trastuzumab 
(n = 35)
Subjects with at least one TEAE, n (%) 10 (28.6) 11 (31.4)
Most common  TEAEsa, n (%)
 Headache 2 (5.7) 3 (8.6)
 Nasal congestion 0 (0) 2 (5.7)
 Nausea 0 (0) 2 (5.7)
Any TEAE related to study drug 5 (14.3) 5 (14.3)
Most common TEAEs related to study  druga, n (%)
 Headache 2 (5.7) 3 (8.6)
 Nausea 0 (0) 2 (5.7)
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